lung cancer Clinical Trials and Research
Also known as: lung carcinoma, bronchogenic carcinoma, nsclc, sclc, pulmonary cancer, lung tumor · ICD-10: C34
Lung cancer is a disease where abnormal cells grow uncontrollably in the lungs. Clinical trial research is actively exploring new therapies, early detection methods, and personalized treatments to improve patient outcomes. Find a Trial helps patients and caregivers search for active lung cancer studies.
Common questions about lung cancer clinical trials
What makes someone eligible for a lung cancer clinical trial?
Eligibility criteria vary widely by study but often include factors like cancer type and stage, previous treatments, and overall health. Researchers use these criteria to ensure patient safety and gather meaningful data, as seen on ClinicalTrials.gov.
What are the different phases of lung cancer clinical trials?
Clinical trials typically progress through phases 1, 2, and 3. Phase 1 studies test safety, phase 2 evaluates effectiveness and side effects, and phase 3 compares new treatments to existing standards, as detailed on ClinicalTrials.gov.
Do clinical trials for lung cancer cost money?
While the investigational treatment and study-related visits are often covered by the trial sponsor, patients may still be responsible for standard medical care costs, such as routine doctor visits or hospital stays. Specific costs vary by trial, according to ClinicalTrials.gov.
What are some active areas of research in lung cancer clinical trials?
Current research focuses on targeted therapies that attack specific cancer cell mutations, immunotherapies that boost the body's immune response, and improved radiation and chemotherapy techniques. Early detection methods and prevention strategies are also key areas, as reported by NIH RePORTER.
What types of interventions are commonly studied in lung cancer trials?
Common interventions include new drug therapies (like targeted drugs or immunotherapies), advanced radiation techniques, surgical approaches, and combinations of these treatments. Trials also explore supportive care and methods to improve quality of life, based on data from ClinicalTrials.gov.
Are there specific biomarkers important in lung cancer clinical trials?
Yes, biomarkers like EGFR mutations, ALK rearrangements, and PD-L1 expression are crucial for identifying patients who might respond to specific targeted or immunotherapies. Research into new biomarkers helps personalize treatment approaches, as evidenced by NIH RePORTER.
What are some common reasons someone might be excluded from a lung cancer trial?
Common exclusion criteria can include certain pre-existing medical conditions, specific prior treatments, other active cancers, or inadequate organ function. These criteria help ensure patient safety and the integrity of study results, as outlined on ClinicalTrials.gov.
Do clinical trials differentiate between types of lung cancer?
Absolutely. Many trials are highly specific, focusing on non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), and even subtypes within NSCLC like adenocarcinoma or squamous cell carcinoma. This specificity allows for more targeted research, according to ClinicalTrials.gov.
How to find a lung cancer trial that fits you
- Describe your lung cancer situation in detail — stage if applicable, prior treatments, age, and other relevant conditions.
- Use the location filter (worldwide, US, US & Canada, Europe) to narrow to trials near you.
- Review each trial's eligibility criteria carefully. Save 2–5 candidates with their NCT numbers.
- Discuss with your treating clinician before contacting the research site.
Browse all lung cancer trials →